Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases-Reference-Cited by-同舟云学术

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases

Published:2021-07-02 Issue:6 Volume:39 Page:1598-1603
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Kaneda Hiroyasu^ORCID,Sawa Kenji,Daga Haruko,Okada Asuka,Nakatani Yuki,Atagi Shinji,Okishio Kyoichi,Tani Yoko,Matsumoto Yoshiya,Ogawa Koichi,Nakahama Kenji,Izumi Motohiro,Mitsuoka Shigeki,Kawaguchi Tomoya

Funder

Eli Lilly Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01147-w.pdf

Reference13 articles.

1. Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

2. Soria JC et al (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378(2):113–125

3. Saito H et al (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20(5):625–635

4. Nakagawa K et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(12):1655–1669

5. Besse B et al (2015) Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized Phase II Study. Clin Cancer Res 21(8):1896–1903

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study);Therapeutic Advances in Medical Oncology;2023-01